Citations 118

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica

Neurology | August 30, 2013 | Volume: 81 | Issue: 14 | Pages: 1197-1204

10.1212/wnl.0b013e3182a6cb5c | PMID 23997151

Randomized controlled trials to assess therapies for multiple sclerosis

Neurology | May 13, 2012 | Volume: 58 | Issue: 8_suppl_4 | Pages: No page available

10.1212/wnl.58.8_suppl_4.s40 | PMID 11971125

The clinical course of neuromyelitis optica (Devic’s syndrome)

Neurology | May 13, 2012 | Volume: 53 | Issue: 5 | Pages: 1107-1107

10.1212/wnl.53.5.1107 | PMID 10496275

Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS

Neurology | May 13, 2012 | Volume: 52 | Issue: 7 | Pages: 1500-1500

10.1212/wnl.52.7.1500 | PMID 10227645

Paraneoplastic encephalomyelitis and seminoma

Neurology | May 13, 2012 | Volume: 51 | Issue: 5 | Pages: 1504-1507

10.1212/wnl.51.5.1504 | PMID 9818899

Multifocal brain MRI artifacts secondary to embolic metal fragments

Neurology | May 13, 2012 | Volume: 49 | Issue: 5 | Pages: 1451-1453

10.1212/wnl.49.5.1451 | PMID 9371940

A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis

Neurology | May 13, 2012 | Volume: 49 | Issue: 2 | Pages: 626-628

10.1212/wnl.49.2.626 | PMID 9270614

Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis

Neurology | May 13, 2012 | Volume: 49 | Issue: 2 | Pages: 378-385

10.1212/wnl.49.2.378 | PMID 9270565

Neuromyelitis optica

Neurology | May 13, 2012 | Volume: 60 | Issue: 5 | Pages: 848-853

10.1212/01.wnl.0000049912.02954.2c | PMID 12629245

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease

Multiple Sclerosis Journal | December 6, 2011 | Volume: 18 | Issue: 1 | Pages: 5-10

10.1177/1352458511431077 | PMID 22146604

Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) are associated with autoantibodies that target aquaporin-4 and, in many cases, multiple other autoantibodies, including antinuclear antibody and antibodies to extractable nuclear antigens. The clinical syndromes that define NMO and NMOSD, especially longitudinally extensive transverse myelitis and optic neuritis, can also occur in the context of established rheumatologic diseases such as systemic lupus erythematosus and Sjögren syndrome and other organ-specific autoimmune diseases. These observations raise questions fundamental to both clinical practice and etiologic research. For example, they could suggest that NMO is one manifestation of a genetic tendency toward humoral autoimmunity. Alternatively, they might indicate that NMO is a central nervous system complication of a multisystem rheumatologic disease. We describe the historical background of this controversy, summarize the current evidence that addresses NMO–systemic autoimmunity relationships, and discuss the practical implications for clinical management.